Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Triptan (5-HT1B/1D agonist)

Almotriptan

Brand names: Almogran

A serotonin 5-HT1B/1D receptor agonist (triptan) used for the acute treatment of migraine attacks with or without aura.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It stimulates 5-HT1B/1D receptors causing cranial vasoconstriction and inhibition of pro-inflammatory neuropeptide release from trigeminal nerve terminals, relieving migraine.

Prescribing in practice

  • As a vasoconstrictor it is contraindicated in ischaemic heart disease, coronary spasm, uncontrolled hypertension and cerebrovascular or peripheral vascular disease.
  • It should be taken to treat an established migraine attack rather than during aura, and overuse can lead to medication-overuse headache.
  • Combination with ergot alkaloids or other triptans must be avoided, and caution is needed with serotonergic drugs because of serotonin syndrome risk.

Monitoring

No routine laboratory monitoring is required; review cardiovascular risk before use and monitor headache frequency to detect medication-overuse headache.

Counselling the patient

  • Take it as soon as the headache phase of a migraine starts, not during warning aura.
  • Limit the number of treatment days each month to avoid rebound headaches.
  • Seek urgent advice if you develop chest tightness or pain after a dose.

Evidence & guidelines

Use is supported by NICE guidance on the management of headaches and migraine, which positions triptans for acute attacks.

Reference: SmPC Almogran; NICE CG150 (Headaches in over 12s 2012, updated 2021); BASH Migraine Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways